ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
Pre-market 13:24:45 | |||
| 75.88 USD | +0.53% |
|
76.3 | +0.56% |
| Sales 2024 * | 51.24B 4,104B | Sales 2025 * | 54.8B 4,389B | Capitalization | 234B 18,759B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 682B | Net income 2025 * | 10.2B 817B | EV / Sales 2024 * | 4.96 x |
| Net Debt 2024 * | 19.9B 1,594B | Net Debt 2025 * | 13.44B 1,077B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
2.06% | Yield 2025 * |
2.14% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
| 1 day | +0.55% | ||
| 1 week | +7.10% | ||
| 1 month | +12.00% | ||
| 3 months | +13.87% | ||
| 6 months | +20.01% | ||
| Current year | +12.67% |
1 week
74.50
76.58
1 month
66.3976.58
Current year
60.4776.58
1 year
60.4776.58
3 years
52.6576.58
5 years
36.1576.58
10 years
25.5576.58
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 30/09/12 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 31/07/21 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 30/09/17 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 31/01/13 |
Philip Broadley
BRD | Director/Board Member | 63 | 26/04/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.38% | 9 M€ | -4.31% | - | |
| 0.99% | 1,182 M€ | -0.33% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 75.88 | +0.53% | 8,547,408 |
| 29/04/24 | 75.48 | +0.41% | 7,538,322 |
| 26/04/24 | 75.17 | +0.19% | 6,687,969 |
| 25/04/24 | 75.03 | +5.38% | 15,606,581 |
| 24/04/24 | 71.2 | +0.49% | 6,137,682 |
Delayed Quote Nasdaq, April 30, 2024 at 09:00 pm
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
20/05/2024
- Investor Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.1
USD
Average target price
164.3
USD
Spread / Average Target
+8.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.00% | 704B | |
| +27.25% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B | |
| -11.01% | 145B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
